Jodi A. Muscal

710 total citations
27 papers, 469 citations indexed

About

Jodi A. Muscal is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Jodi A. Muscal has authored 27 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Neurology and 7 papers in Oncology. Recurrent topics in Jodi A. Muscal's work include Neuroblastoma Research and Treatments (12 papers), Glioma Diagnosis and Treatment (6 papers) and Cancer therapeutics and mechanisms (5 papers). Jodi A. Muscal is often cited by papers focused on Neuroblastoma Research and Treatments (12 papers), Glioma Diagnosis and Treatment (6 papers) and Cancer therapeutics and mechanisms (5 papers). Jodi A. Muscal collaborates with scholars based in United States, Canada and China. Jodi A. Muscal's co-authors include Patrick A. Thompson, Susan M. Blaney, Stacey L. Berg, Jed G. Nuchtern, Ashish M. Ingle, Brenda J. Weigel, Joel M. Reid, Charlotte H. Ahern, Terzah M. Horton and Brian Gibson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Jodi A. Muscal

27 papers receiving 464 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jodi A. Muscal United States	13	249	142	124	78	75	27	469
Kevin C. De Braganca United States	13	272 1.1×	196 1.4×	108 0.9×	152 1.9×	267 3.6×	34	613
Kenji Wakiya Japan	10	229 0.9×	105 0.7×	78 0.6×	41 0.5×	84 1.1×	24	477
Patricia Rakopoulos Canada	7	327 1.3×	68 0.5×	86 0.7×	64 0.8×	219 2.9×	9	596
Shuji Momose Japan	14	201 0.8×	208 1.5×	48 0.4×	87 1.1×	70 0.9×	46	521
Angela Queisser Germany	15	240 1.0×	180 1.3×	106 0.9×	114 1.5×	37 0.5×	18	603
Nicholas Murray United Kingdom	10	224 0.9×	168 1.2×	304 2.5×	94 1.2×	31 0.4×	19	669
Weifen Zeng United States	9	173 0.7×	131 0.9×	72 0.6×	34 0.4×	81 1.1×	12	416
Angela J. Waanders United States	12	214 0.9×	109 0.8×	101 0.8×	101 1.3×	160 2.1×	45	481
Yutaka Shimazu Japan	8	321 1.3×	124 0.9×	68 0.5×	20 0.3×	110 1.5×	21	535
Akiyoshi Ogino Japan	15	199 0.8×	99 0.7×	90 0.7×	66 0.8×	215 2.9×	33	533

Countries citing papers authored by Jodi A. Muscal

Since Specialization

Citations

This map shows the geographic impact of Jodi A. Muscal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jodi A. Muscal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jodi A. Muscal more than expected).

Fields of papers citing papers by Jodi A. Muscal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jodi A. Muscal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jodi A. Muscal. The network helps show where Jodi A. Muscal may publish in the future.

Co-authorship network of co-authors of Jodi A. Muscal

This figure shows the co-authorship network connecting the top 25 collaborators of Jodi A. Muscal. A scholar is included among the top collaborators of Jodi A. Muscal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jodi A. Muscal. Jodi A. Muscal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mascarenhas, Leo, Chitose Ogawa, Theodore W. Laetsch, et al.. (2021). Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Medicine. 10(3). 843–856. 2 indexed citations

Cheng, Lily S., et al.. (2021). Surgical Approach to Pediatric Ovarian Growing Teratoma Syndrome: A Case Report. Journal of Pediatric and Adolescent Gynecology. 34(6). 876–881. 1 indexed citations

Muscal, Jodi A., et al.. (2020). Prevention of Recurrent Mucinous Borderline Ovarian Tumor with Aromatase Inhibitor. Journal of Pediatric and Adolescent Gynecology. 33(5). 610–612. 2 indexed citations

Cruz, Filemon S. Dela, Elizabeth Fox, Jodi A. Muscal, et al.. (2020). A phase I/II study of lenvatinib (LEN) plus everolimus (EVE) in recurrent and refractory pediatric solid tumors, including CNS tumors.. Journal of Clinical Oncology. 38(15_suppl). 10527–10527. 5 indexed citations

Ludwig, Joseph A., Noah Federman, Peter M. Anderson, et al.. (2020). 1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma. Annals of Oncology. 31. S972–S972. 10 indexed citations

Esbenshade, Adam J., Lisa S. Kahalley, Reto M. Baertschiger, et al.. (2019). Mentors’ perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 66(10). e27920–e27920. 5 indexed citations

Foster, Jennifer H., Jodi A. Muscal, Charles G. Minard, et al.. (2019). Phase 1 study of pevonedistat (MLN4924) in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).. Journal of Clinical Oncology. 37(15_suppl). e21521–e21521. 1 indexed citations

Kogiso, Mari, Lin Qi, Frank Braun, et al.. (2018). Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models. Clinical Cancer Research. 24(9). 2159–2170. 19 indexed citations

Shulman, David S., Kieuhoa T. Vo, Elizabeth Fox, et al.. (2018). Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas.. Journal of Clinical Oncology. 36(15_suppl). 10542–10542. 4 indexed citations

10.

Esbenshade, Adam J., Christopher R. Pierson, Amanda L. Thompson, et al.. (2017). Long‐term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 65(3). 7 indexed citations

11.

Childress, Krista, Ninad Patil, Jodi A. Muscal, Jennifer E. Dietrich, & Rajkumar Venkatramani. (2017). Borderline Ovarian Tumor in the Pediatric and Adolescent Population: A Case Series and Literature Review. Journal of Pediatric and Adolescent Gynecology. 31(1). 48–54. 23 indexed citations

12.

Lu, Jiaxiong, Shan Guan, Yanling Zhao, et al.. (2017). The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. Cancer Letters. 400. 61–68. 28 indexed citations

13.

Rojas, Yesenia, Bethany J. Slater, Michael Baker, et al.. (2016). Childhood and adolescent tracheobronchial mucoepidermoid carcinoma (MEC): a case-series and review of the literature. Pediatric Surgery International. 32(4). 417–424. 12 indexed citations

14.

Thompson, Patrick A., Rachid Drissi, Jodi A. Muscal, et al.. (2013). A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112). Clinical Cancer Research. 19(23). 6578–6584. 61 indexed citations

15.

Muscal, Jodi A., Patrick A. Thompson, Terzah M. Horton, et al.. (2012). A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916). Pediatric Blood & Cancer. 60(3). 390–395. 66 indexed citations

16.

Muscal, Jodi A., Kathleen A. Scorsone, Linna Zhang, Jeffrey Ecsedy, & Stacey L. Berg. (2012). Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Investigational New Drugs. 31(1). 39–45. 35 indexed citations

17.

Muscal, Jodi A., Philip A. Thompson, Charlotte H. Ahern, et al.. (2011). A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group study.. Journal of Clinical Oncology. 29(15_suppl). 9522–9522. 1 indexed citations

18.

Muscal, Jodi A., Yongkai Sun, Jed G. Nuchtern, et al.. (2011). Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemotherapy and Pharmacology. 69(4). 943–947. 40 indexed citations

19.

Muscal, Jodi A., Patrick A. Thompson, Vincent L. Giranda, et al.. (2009). Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemotherapy and Pharmacology. 65(3). 419–425. 28 indexed citations

20.

Muscal, Jodi A., Jeremy Jones, Arnold C. Paulino, et al.. (2008). Changes Mimicking New Leptomeningeal Disease After Intensity-Modulated Radiotherapy for Medulloblastoma. International Journal of Radiation Oncology*Biology*Physics. 73(1). 214–221. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact